Baker Bros. Advisors 13F: Adds $220M to PRAX Stake

Baker Bros. Advisors Expands Position in PRAX

Baker Bros. Advisors grew its investment in Praxis Precision Medicines, Inc. (NasdaqGS: PRAX) during the period, adding 626,710 shares to bring its total stake to 1,753,198 shares. The 55.6% increase brought the reported value of the position to about $614.6 million, according to the fund's Form 13F filed with the SEC for the quarter ended May 15, 2026. Institutional 13F filings look backward at holdings from the end of the reporting period and may not reflect current trades.

PRAX Shares Hover Near Upper Bounds

Shares of Praxis Precision Medicines trade near $350.56, placing the stock well above its 200-day moving average of $314.89 and close to its 52-week high of $392.70. The biotechnology firm carries a market capitalization of roughly $8.34 billion and a beta of 2.78, reflecting higher-than-average price swings compared to the broader market.

Insider Buying and Selling at Praxis Precision Medicines, Inc.

Insider activity at the company included transactions by Jill Desimone on June 24, 2026. Desimone acquired 11,600 shares at an average price of $71.20 per share, totaling about $825,953. On the same date, Desimone also disposed of 11,600 shares in a transaction reported with a zero-dollar cost basis. Insider sales do not inherently signal a negative outlook and often form part of routine personal financial planning.

Analysts Set New Price Targets

Analyst coverage for Praxis Precision Medicines reflects strong optimism from Wall Street firms. On October 16, 2026, JP Morgan initiated coverage with an Overweight rating and a $700.00 price target. UBS followed suit on October 15, 2026, starting with a Buy rating and a $706.00 target. HC Wainwright & Co. reiterated its Buy rating with a $1,201.00 target on October 15, 2026. Across 19 analyst opinions, the stock holds a consensus strong buy rating with a mean target price of $638.68.

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines is a clinical-stage biopharmaceutical enterprise based in Boston, Massachusetts. The company develops therapies for central nervous system disorders stemming from neuronal excitation-inhibition imbalances. Its pipeline features candidates such as ulixacaltamide for essential tremor and relutrigine for epileptic encephalopathies.

What to Watch at Praxis Precision Medicines, Inc.

Investors tracking Praxis Precision Medicines will look toward the company's upcoming earnings release scheduled for November 9, 2026. Future regulatory updates on its clinical pipeline and subsequent institutional filings will provide further insight into how major funds manage their positions.